Jacob Thaysen is recorded as Board Member at Illumina, Inc. (ILMN) since January 1, 2023 and CEO at Illumina, Inc. (ILMN). The newest filing on record that lists Jacob Thaysen as Board Member at Illumina, Inc. (ILMN) is dated April 9, 2026. Agilent Technologies, Inc. reported in an 8-K filed September 5, 2023 that Jacob Thaysen resigned as Senior Vice President of the Company, and president, Life Sciences and Applied Markets Group (LSAG), effective September 5, 2023. Illumina, Inc. reported in an 8-K filed September 5, 2023 that Jacob Thaysen was appointed member of the Board, effective September 25, 2023. Illumina, Inc. reported in an 8-K filed September 5, 2023 that Jacob Thaysen was appointed Chief Executive Officer, effective September 25, 2023. The proxy statement of Illumina, Inc. reports total compensation of $11,018,895 for Jacob Thaysen in fiscal 2025, including a base salary of $1,000,000. Disclosed compensation is on record for 3 fiscal years. Jacob Thaysen has spoken on 9 earnings calls and 1 other investor event across 1 company, most recently for Illumina, Inc. on November 10, 2026. Illumina, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Illumina, Inc. includes Jay T. Flatley (Chairman), John W. Thompson (Chairman), Scott Gottlieb (Chairman and Board Member) and 7 others.
“Agilent Technologies, Inc. (the “Company”) announced that Jacob Thaysen resigned as Senior Vice President of the Company, and president, Life Sciences and Applied Markets Group (LSAG), effective September 5, 2023.”
Agilent Technologies, Inc. Form 8-K, filed September 5, 2023
· Read the filing
“the Board of Directors (the "Board") of the Company had appointed Jacob Thaysen to serve as Chief Executive Officer on a permanent basis and as a member of the Board, in each case, effective as of September 25, 2023 (the "Commencement Date").”
Illumina, Inc. Form 8-K, filed September 5, 2023
· Read the filing
Jacob Thaysen on recent calls
“And let me start by saying this year has been fantastic for Illumina. We have had great momentum in the market. Q3 went very well. We were beating the expectation for Q3 and also raised for Q4, so raised for the full year, both on the The top line and the bottom line, so we feel really good where we are.”
“We are off to a great start in 2026, with Q1 revenue, margin, and EPS all coming in above our guidance range. Our solid performance reflects disciplined execution across the organization along with strength in our clinical markets and growth across all regions excluding China.”
“In the third quarter, we delivered another strong performance with revenue, non-GAAP operating margin and diluted EPS all above our guidance range. We reported total revenue of $1.08 billion, and we returned to growth excluding China, up about 2% year-over-year.”
“In the second quarter, despite a year-over-year decline, we delivered revenue at the high end of our guidance range at approximately $1.06 billion. At the same time, the team's strong execution drove profitability above expectations with a non-GAAP operating margin of 23.8% and a non-GAAP EPS of $1.19.”
“Before we begin, I want to take a moment to recognize our former chair of the board of directors, Steve MacMillan, for his leadership in strengthening Illumina’s position in genomics innovation.”
